| Literature DB >> 24204794 |
Lauren D Arnold1, Melissa Braganza, Rondek Salih, Graham A Colditz.
Abstract
BACKGROUND: Statistical training across the continuum of medical education may not have advanced at the pace of statistical reporting in the medical literature, yet a comprehensive understanding of statistical concepts most commonly presented in current research is critical to the effective practice of Evidence Based Medicine. The objective of this content analysis was to describe statistical techniques used in a leading medical journal, JAMA, across a 20-year period, with a focus on implications for medical education. METHODS ANDEntities:
Mesh:
Year: 2013 PMID: 24204794 PMCID: PMC3813707 DOI: 10.1371/journal.pone.0077301
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Flow chart outlining selection criteria of articles for content analysis.
Characteristics of 361 articles published in JAMA, 1990, 2000, 2010.
| Article Year | |||||
| Characteristics | Total | 1990 (n = 133) | 2000 (n = 122) | 2010 (n = 106) | p-value |
| Study Design | <0.001 | ||||
| Descriptive† | 55 (15.2%) | 34 (25.6%) | 9 (7.4%) | 12 (11.3%) | |
| Cross-sectional | 52 (14.4%) | 24 (18.0%) | 21 (17.2%) | 7 (6.6%) | |
| Case control‡ | 19 (5.3%) | 10 (7.5%) | 5 (4.1%) | 4 (3.8%) | |
| Cohort | 56 (15.5%) | 9 (6.8%) | 23 (18.9%) | 24 (22.6%) | |
| Meta-analysis/systematic review | 25 (6.9%) | 3 (2.3%) | 5 (4.1%) | 17 (16.0%) | |
| RCT | 67 (18.6%) | 14 (10.5%) | 30 (24.6%) | 23 (21.7%) | |
| Other | 87 (24.1) | 39 (29.3) | 29 (23.8) | 19 (17.9) | |
| Statistical software | |||||
| SAS | 90 (24.9%) | 7 (5.3%) | 31 (25.4%) | 52 (49.1%) | <0.001 |
| SPSS | 23 (6.4%) | 3 (2.3%) | 6 (4.9%) | 14 (13.2%) | 0.002 |
| STATA | 41 (11.4%) | 0 (0.0%) | 7 (5.7%) | 34 (32.1%) | <0.001 |
| Not specified | 152 (42.1%) | 90 (83.3%) | 61 (52.6%) | 1 (1.0%) | <0.001 |
| Biospecimen data | 124 (34.3%) | 50 (37.6) | 44 (36.1) | 30 (28.3) | 0.287 |
| Lab values used/ measured | 130 (36.0%) | 54 (40.6) | 45 (36.9) | 31 (29.2) | 0.186 |
Chi-square for difference by year; †Includes case studies, comparative studies; ‡Inlcudes nested case control.
Primary focus of 361 articles published in JAMA 1990, 2000, 2010.
| Article Focus | Frequency |
| New therapeutic uses | 56 (15.5%) |
| Healthcare issues | 46 (12.7%) |
| Chronic disease† | 41 (11.4%) |
| Heart disease | 34 (9.4%) |
| Maternal child health‡ | 31 (8.6%) |
Includes topics such as cost-effectiveness of care, quality of care, and Medicare; †Excluding heart disease; includes ALS, asthma, food allergies, sickle cell, and thyroid disorders; ‡Includes reproductive/sexual health.
Statistical measures and methods in JAMA articles published in 1990, 2000, and 2010*.
| Article Year | ||||
| Characteristics | 1990 (n = 133) | 2000 (n = 122) | 2010 (n = 106) | p-value |
| Descriptive statistics | 124 (93.2%) | 122 (100%) | 106 (100%) | - |
| Low-level statistical measures† | 108 (81.2%) | 116 (95.1%) | 105 (99.1%) | <0.001 |
| Morbidity & mortality | 76 (57.1%) | 60 (49.2%) | 73 (68.9%) | 0.011 |
| ANOVA | 26 (19.5%) | 24 (19.7%) | 18 (17.0) | 0.844 |
| Chi square | 54 (40.6%) | 51 (41.8%) | 51 (48.1%) | 0.471 |
| Fisher exact | 19 (14.3%) | 18 (14.8%) | 20 (18.9%) | 0.583 |
| Mantel-Haenszel | 11 (8.3%) | 15 (12.3%) | 7 (6.6%) | 0.301 |
| Epidemiologic statistics‡ | 28 (21.1%) | 34 (27.9%) | 33 (31.1%) | 0.190 |
| t-test | 28 (21.1%) | 31 (25.4%) | 28 (26.4%) | 0.577 |
| Power | 7 (5.3%) | 7 (5.7%) | 28 (26.4%) | <0.001 |
| p-trend | 6 (4.5%) | 17 (13.9%) | 14 (13.2%) | 0.023 |
| Pearson correlation coefficient | 13 (9.8%) | 10 (8.2%) | 5 (4.7%) | 0.340 |
| Logistic regression | 27 (20.3%) | 42 (34.4%) | 28 (26.4%) | 0.039 |
| Simple linear regression | 12 (9.0%) | 17 (13.9%) | 13 (12.3%) | 0.460 |
| Poisson regression | 0 (0.0%) | 11 (9.0%) | 8 (7.5%) | 0.003 |
| Log-rank test | 2 (1.5%) | 9 (7.4%) | 15 (14.2%) | 0.001 |
| Multi-level modeling | 3 (2.3%) | 11 (9.0%) | 34 (32.1%) | <0.001 |
| Multiple comparison | 7 (5.3%) | 8 (6.6%) | 9 (8.5%) | 0.609 |
| Multiple regression | 32 (24.1%) | 52 (42.6%) | 51 (48.1%) | <0.001 |
| Non parametric test | 17 (12.8%) | 19 (15.6%) | 23 (21.7%) | 0.173 |
| Wilcoxon Rank | 13 (9.8%) | 14 (11.5%) | 19 (17.9%) | 0.150 |
| Survival analysis | 19 (14.3%) | 27 (22.1%) | 46 (43.4%) | <0.001 |
| Cox models | 10 (7.5%) | 17 (13.9%) | 34 (32.1%) | <0.001 |
| Kaplan Meier | 5 (3.8%) | 13 (10.7%) | 24 (22.6%) | <0.001 |
| Sensitivity analysis | 30 (22.6%) | 44 (36.1%) | 52 (49.1%) | <0.001 |
| Intention to treat | 6 (4.5%) | 18 (14.8%) | 24 (22.6%) | <0.001 |
| Transformation | 9 (6.8%) | 12 (9.8%) | 10 (9.4%) | 0.6374 |
Excludes statistics in which there were n<15 across all three years of review; Includes standard deviations, standard errors, confidence intervals, and p-values; ‡Includes odds ratios, relative risks, attributable risk, sensitivity, and specificity.